One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Flashback Foreword: Anti-HER2 Monoclonal Antibody as a Single Agent.
Goodwin, Pamela J. MD, MSc 1,2,,
doi : 10.1200/JCO.22.02679
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease .
Cobleigh, Melody A.; Vogel, Charles L.; Tripathy, Debu; Robert, Nicholas J.; Scholl, Susy; Fehrenbacher, Louis; Wolter, Janet M.; Paton, Virginia; Shak, Steven; Lieberman, Gracie; Slamon, Dennis J.
doi : 10.1200/JCO.22.02510
Overexpression of the HER2 protein occurs in 25% to 30% of human breast cancers and leads to a particularly aggressive form of the disease. Efficacy and safety of recombinant humanized anti-HER2 monoclonal antibody as a single agent was evaluated in women with HER2-overexpressing metastatic breast cancer that had progressed after chemotherapy for metastatic disease.
POLARized Risk for Local Recurrence on the Basis of Tumor Biology: Is It That Simple?.
Torres, Mylin A. MD 1,,
doi : 10.1200/JCO.22.02375
FOxTROT: Are We Ready to Dance?.
Taieb, Julien MD, PhD 1,,; Karoui, Mehdi MD, PhD 2
doi : 10.1200/JCO.22.02108
Incorporating Information From Proxies for Patient-Centered Outcomes in Adult and Pediatric Oncology Settings.
Roydhouse, Jessica PhD 1,2,,; Reeve, Bryce B. PhD 3,
doi : 10.1200/JCO.22.01049
What is in a Name? Consequences of the Classification Schism in Hematopathology.
Aster, Jon C. MD, PhD 1
doi : 10.1200/JCO.22.02680
Cognitive and Behavioral Development of 9-Year-Old Children After Maternal Cancer During Pregnancy: A Prospective Multicenter Cohort Study.
Van Assche, Indra A. MSc 1; Huis 't Veld, Evangeline A. in MSc 2,3; Van Calsteren, Kristel MD, PhD 1,4; van Gerwen, Mathilde PhD 2,3,5; Blommaert, Jeroen PhD 6,7,8; Cardonick, Elyce MD, PhD 9; Halaska, Michael J. MD, PhD 10; Fruscio, Robert MD, PhD 11; Fumagalli, Monica MD, PhD 12,13; Lemiere, Jurgen PhD 6,14,; van Dijk-Lokkart, Elisabeth M. PhD 5,15; Fontana, Camilla PhD 13; van Tinteren, Harm PhD 2; De Ridder, Jessie MD, PhD 16,17; van Grotel, Martine MD, PhD 2; van den Heuvel-Eibrink, Marry M. MD, PhD 2,18; Lagae, Lieven MD, PhD 1,16,; Amant, Frederic MD, PhD 3,7,19,,
doi : 10.1200/JCO.22.02005
Development and Validation of a Genomic Profile for the Omission of Local Adjuvant Radiation in Breast Cancer.
Sjostrom, Martin MD, PhD 1,2,; Fyles, Anthony MD 3; Liu, Fei-Fei MD 3; McCready, David MD 3,; Shi, Wei MSc 3; Rey-McIntyre, Katrina MBA, BSc 3; Chang, S. Laura PhD 4,; Feng, Felix Y. MD 2,; Speers, Corey W. MD, PhD 5,; Pierce, Lori J. MD 5,; Holmberg, Erik PhD 6,; Ferno, Marten PhD 1,; Malmstrom, Per MD, PhD 1,7,; Karlsson, Per MD, PhD 6,
doi : 10.1200/JCO.22.00655
Adjuvant radiotherapy (RT) is used for women with early-stage invasive breast cancer treated with breast-conserving surgery. However, some women with low risk of recurrence may safely be spared RT.
Preoperative Chemotherapy for Operable Colon Cancer: Mature Results of an International Randomized Controlled Trial.
Morton, Dion MD 1; Seymour, Matthew MD 2,; Magill, Laura PhD 3,; Handley, Kelly PhD 3; Glasbey, James MD 1; Glimelius, Bengt MD 4,; Palmer, Andy 3; Seligmann, Jenny MD 2,; Laurberg, Soren MD 5; Murakami, Keigo MD 6; West, Nick MD 6,; Quirke, Philip FMedSci 6,; Gray, Richard MSc 7; on behalf of the FOxTROT Collaborative Group
doi : 10.1200/JCO.22.00046
Neoadjuvant chemotherapy (NAC) has potential advantages over standard postoperative chemotherapy for locally advanced colon cancer but requires formal evaluation.
Molecular Classification of Appendiceal Adenocarcinoma.
Foote, Michael B. MD 1; Walch, Henry MS 2; Chatila, Walid PhD 2,3; Vakiani, Efsevia MD, PhD 4; Chandler, Chris MD 5; Steinruecke, Felix BS 1; Nash, Garrett M. MD 5,; Stadler, Zsofia MD 1,; Chung, Sebastian MD 5; Yaeger, Rona MD 1,; Braghrioli, Maria Ignez MD 6,; Shia, Jinru MD 4,; Kemel, Yelena MS, ScM 7; Maio, Anna BSN, RN 7; Sheehan, Margaret MS 7; Rousseau, Benoit MD, PhD 1,; Argiles, Guillem MD 1,; Berger, Michael PhD 2,3,; Solit, David MD 2,3,; Schultz, Nikolaus PhD 2,3; Diaz, Luis A. Jr MD 1,; Cercek, Andrea MD 1,
doi : 10.1200/JCO.22.01392
Appendiceal adenocarcinomas (ACs) are rare, histologically diverse malignancies treated as colorectal cancers despite having distinct biology and clinical behavior. To guide clinical decision making, we defined molecular subtypes of AC associated with patient survival, metastatic burden, and chemotherapy response.
Long-Term Morbidity and Mortality Among Survivors of Neuroblastoma Diagnosed During Infancy: A Report From the Childhood Cancer Survivor Study.
Friedman, Danielle Novetsky MD, MS 1,2,,; Goodman, Pamela J. MS 3; Leisenring, Wendy M. ScD 3,; Diller, Lisa R. MD 4,; Cohn, Susan L. MD 5,; Howell, Rebecca M. PhD 6,; Smith, Susan A. MPH 6; Tonorezos, Emily S. MD, MPH 7,; Wolden, Suzanne L. MD 1,2; Neglia, Joseph P. MD, MPH 8; Ness, Kirsten K. PhD 9; Gibson, Todd M. PhD 7; Nathan, Paul C. MD, MSc 10; Weil, Brent R. MD 4,11; Robison, Leslie L. PhD 9; Oeffinger, Kevin C. MD 12; Armstrong, Gregory T. MD, MSCE 9,; Sklar, Charles A. MD 1,2,; Henderson, Tara O. MD, MPH 5,
doi : 10.1200/JCO.22.01732
To describe the risk of late mortality, subsequent malignant neoplasms (SMNs), and chronic health conditions (CHCs) in survivors of neuroblastoma diagnosed in infancy by treatment era and exposures.
Cost-Effectiveness Analysis of Frontline Polatuzumab-Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone and/or Second-Line Chimeric Antigen Receptor T-Cell Therapy Versus Standard of Care for Treatment of Patients With Intermediate- to High-Risk Diffuse Large B-Cell Lymphoma.
Vijenthira, Abi MD, SM 1; Kuruvilla, John MD 1,; Crump, Michael MD 1,; Jain, Michael MD, PhD 2,; Prica, Anca MD, MSc 1,,
doi : 10.1200/JCO.22.00478
Recent studies of polatuzumab vedotin and CD19 chimeric antigen receptor T-cell therapy (CAR-T) have shown significant improvements in progression-free survival over standard of care (SOC) for patients with diffuse large B-cell lymphoma.
Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial.
Dimopoulos, Meletios A. MD 1,,; Oriol, Albert MD 2,; Nahi, Hareth MD, PhD 3,; San-Miguel, Jesus MD, PhD 4,; Bahlis, Nizar J. MD 5,; Usmani, Saad Z. MD, MBA 6,; Rabin, Neil MBBS, PhD 7,; Orlowski, Robert Z. MD, PhD 8,; Suzuki, Kenshi MD, PhD 9; Plesner, Torben MD 10,; Yoon, Sung-Soo MD, PhD 11,; Ben Yehuda, Dina MD 12; Richardson, Paul G. MD 13,; Goldschmidt, Hartmut MD 14,; Reece, Donna MD 15,; Ahmadi, Tahamtan MD, PhD 16,; Qin, Xiang MS 17,; Garvin Mayo, Wendy APRN, ANP-BC, MSN 18; Gai, Xue MMed 19,; Carey, Jodi BSN 17,; Carson, Robin MD 17,; Moreau, Philippe MD 20,
doi : 10.1200/JCO.22.00940
With the initial analysis of POLLUX at a median follow-up of 13.5 months, daratumumab in combination with lenalidomide and dexamethasone (D-Rd) significantly prolonged progression-free survival versus lenalidomide and dexamethasone (Rd) alone in patients with relapsed or refractory multiple myeloma (RRMM).
Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial.
Sonneveld, Pieter MD, PhD 1,,; Chanan-Khan, Asher MD 2,; Weisel, Katja MD 3,; Nooka, Ajay K. MD 4,; Masszi, Tamas MD 5,; Beksac, Meral MD 6,; Spicka, Ivan MD, PhD 7,; Hungria, Vania MD 8,; Munder, Markus MD 9,; Mateos, Maria-Victoria MD, PhD 10,; Mark, Tomer M. MD 11,; Levin, Mark-David MD, PhD 12,; Ahmadi, Tahamtan MD 13,; Qin, Xiang MS 14,; Garvin Mayo, Wendy MSN 15; Gai, Xue MMeD 16,; Carey, Jodi BSN 14,; Carson, Robin MD 14,; Spencer, Andrew MD 17,
doi : 10.1200/JCO.21.02734
At the primary analysis of CASTOR (median follow-up, 7.4 months), daratumumab plus bortezomib and dexamethasone (D-Vd) significantly prolonged progression-free survival versus bortezomib and dexamethasone (Vd) alone in relapsed or refractory multiple myeloma (RRMM).
Effect of the COVID-19 Pandemic on Place of Death Among Medicaid and Commercially Insured Patients With Cancer in Washington State.
Panattoni, Laura E. PhD 1,2,; McDermott, Cara L. PharmD, PhD 1,3; Li, Li MA, MPA 1; Sun, Qin MPA 1; Fedorenko, Catherine R. MMSci 1; Sanchez, Hayley A. MPH 1; Kreizenbeck, Karma L. BA 1; Shankaran, Veena MD 1,; Ramsey, Scott D. MD, PhD 1,,
doi : 10.1200/JCO.22.00070
The COVID-19 pandemic-related disruptions in health care delivery might have affected end-of-life care in patients with cancer. We examined changes in place of death and hospice support for Medicaid and commercially insured patients during the pandemic.
Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma.
Coleman, Jonathan A. MD 1,,; Yip, Wesley MD 1,; Wong, Nathan C. MD 1; Sjoberg, Daniel D. PhD 1,; Bochner, Bernard H. MD 1,; Dalbagni, Guido MD 1; Donat, S. Machele MD 1; Herr, Harry W. MD 1; Cha, Eugene K. MD 1; Donahue, Timothy F. MD 1; Pietzak, Eugene J. MD 1,; Hakimi, A. Ari MD 1,; Kim, Kwanghee PhD 1,; Al-Ahmadie, Hikmat A. MD 1,; Vargas, H. Alberto MD 1; Alvim, Ricardo G. MD 1; Ghafoor, Soleen MD 1; Benfante, Nicole E. BS 1; Meraney, Anoop M. MD 2; Shichman, Steven J. MD 2; Kamradt, Jeffrey M. MD 2; Nair, Suresh G. MD 3; Baccala, Angelo A. Jr MD 3,; Palyca, Paul MD 3; Lash, Bradley W. MD 3; Rizvi, Muhammad A. MD 3; Swanson, Scott K. MD 4; Muina, Antonio F. MD 5; Apolo, Andrea B. MD 6; Iyer, Gopa MD 1,; Rosenberg, Jonathan E. MD 1,; Teo, Min Y. MD 1,; Bajorin, Dean F. MD 1,
doi : 10.1200/JCO.22.00763
Neoadjuvant chemotherapy (NAC) has proven survival benefits for patients with invasive urothelial carcinoma of the bladder, yet its role for upper tract urothelial carcinoma (UTUC) remains undefined.
Informative Censoring of Progression-Free Survival Data in the TROPiCS-02 Trial: An Unrecognized Bias.
Li, Guo-Fu PhD; Qiao, Yu-Wei BM; Guan, Ai-Jia BM; Yu, Guo PhD
doi : 10.1200/JCO.22.02234
Triple-Negative Receptor Conversion at Metastatic Sites Might Show Better Efficacy in Patients Who Received Sacituzumab Govitecan.
Altundag, Kadri MD
doi : 10.1200/JCO.22.01961
Sacituzumab Govitecan in Hormone Receptor-Positive Metastatic Breast Cancer.
Sg, Nithin MD; Gogia, Ajay MD, MBBS
doi : 10.1200/JCO.22.02113
Reply to G.-F. Li et al, K. Altundag, and N. SG et al.
Rugo, Hope S. MD; Bardia, Aditya MD, MPH; Tolaney, Sara M. MD, MPH
doi : 10.1200/JCO.22.02541
Erratum: CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study.
doi : 10.1200/JCO.22.02888
Erratum: DaBlaCa-13 Study: Oncological Outcome of Short-Term, Intensive Chemoresection With Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial.
doi : 10.1200/JCO.22.02889
